Clinical trials: Blood Pressure Reduction
Hypertension
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
This study will be compare Felodipine sustained-release tablets, to Lercanidipine hydrochloride tablets (Zanidip®) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on…
- Trial name
- Zanidip (NCT01520285)
- Testing
- Zanidip, Felodipine sustained-release tablet
- Where
- China
- Volunteers
- 281 people
- Sponsor
- Lee's Pharmaceutical Limited
High Risk Cardiovascular Disease, Hypertension
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
- Conditions
- High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
- Trial name
- ZENITH (NCT07181109)
- Testing
- Zilebesiran
- Where
- 1,190 sites in United States, Argentina and 33 more
- Volunteers
- 11,000 people
- Sponsor
- Alnylam Pharmaceuticals
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases
Evaluating the Effectiveness of a Computerized Medication Adherence System at Reducing Cardiovascular Disease Risk Factors
High blood pressure and high cholesterol are both causes of cardiovascular disease (CVD), and it is important for people with these conditions to adhere to their medication regimens.
- Trial name
- NCT00796172
- Testing
- Medication Adherence System (MAS), Usual Care
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- PHCC LP
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in…
- Trial name
- NCT00434967
- Testing
- Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg
- Where
- 27 sites in Belgium, Latvia and 4 more
- Volunteers
- 2,207 people
- Sponsor
- AstraZeneca
Hypertension
Magneto-rheology to Lower Blood Pressure
Heart attacks and strokes are the leading causes of death in US. High blood viscosity and turbulence in blood flow are the key for cardiovascular diseases.
- Trial name
- NCT03783117
- Testing
- Magnetic field treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cardiovascular Therapy LLC